



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, **Indore** - 452001 (M.P.)

Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

Date: 11th February, 2022

To,

The Secretary,
Department of Corporate Services,
Bombay Stock Exchange Limited (BSE),
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai – 400001

Scrip Code: 524606

Sub.: Disclosure of Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sirs,

Pursuant to Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors in its Board Meeting held on 11.02.2022 has approved the Unaudited Financial Results of the Company for the Quarter ended 31.12.2021.

We hereby request you to kindly acknowledge the receipts of same.

Thanking You,

Yours Sincerely

For Beryl Drugs Limited


Sudhir Sethi
Chairman & Director
DIN: 00090172





BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-2517677
E-mail : beryldrugs25@yahoo.com

ANNEXURE I

Submission of Unaudited Financial Result by Companies Other than Banks

(Rs in 000)

Part I

Statement of standalone Unaudited Result for the Quarter ended 31/12/2021

Particulars	3 months ended (31-12-2021)		Quarter ended		Nine Months ended		Year ended	
	3 months ended (31-12-2021)		Preceding 3 months ended (30-09-2021)		Year to date figures for current period ended (31-12-2021)		Year to date figures for previous period ended (31-12-2020)	
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
1 Revenue From Operations								
Net sales or Revenue from Operations	31806		33442		20626		80282	
Other operating revenues	383		368		341		5773	
	32189		33810		20967		86055	
2 Expenses								
(a) Cost of materials consumed	17105		17484		14591		49826	
(b) Purchases of stock-in-trade	0		0		0		0	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	81		1271		-7370		-11077	
(d) Employee benefit expense	3914		3263		3339		8490	
(e) Finance costs	1154		1105		926		3245	
(f) Depreciation and amortisation expense	2718		2448		3458		10376	
(g) Other Expenses	8639		12723		8712		24872	
	33611		38294		23656		85732	
3 Profit (loss) from operations before exceptional and extraordinary items and tax	-1422		-4484		-2689		323	
4 Exceptional items	0		0		0		0	
5 Profit (loss) before extraordinary items and tax	-1422		-4484		-2689		323	
6 Extraordinary items	0		0		0		0	
7 Profit (loss) before tax	-1422		-4484		-2689		323	
8 Tax Expense								
Current tax	0		0		8		468	
Deferred tax	-403		-262		-994		-1369	
Income tax earlier years	0		0		0		0	
	-403		-262		-986		-901	
Total Tax Expenses	-1019		-4222		-1703		1224	
9 Net Profit (loss) for the period from continuing operations	0		0		0		0	
10 Net Profit (loss) from discontinuing operations before tax	0		0		0		0	
11 Tax Expense of discontinuing operations	0		0		0		0	
12 Net Profit (loss) from discontinuing operations after tax	0		0		0		0	
Net Profit (loss) for the Period	-1019		-4222		-1703		1224	
13	-36		403		-808		73	
Other comprehensive income	-1055		-3819		-2511		1297	
14								
15								
Details of equity share capital								
Paid-up equity share capital	50717		50717		50717		50717	
Face value of equity share capital	10		10		10		10	
Earnings per share								
i Basic earnings per share before extraordinary items	-0.20		-0.83		-0.34		0.24	
ii Diluted earnings per share before extraordinary items	-0.20		-0.83		-0.34		0.24	

Notes... Contd... Page 2

Place : Indore
Date : 11.02.2022

Sanjay Sethi
Managing Director
DIN : 00090277

BERYL DRUGS LTD.
(Director)



BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-2517677
E-mail : beryldrugs25@yahoo.com

Notes :

- 1 These results have been prepared as per Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 and in accordance with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules 2015 as amended and other accounting principles generally accepted in India.
- 2 The figures for the quarter and nine month ended on 31st December, 2021 are the balancing figures between unaudited figures in respect of the nine month ended on December 31, 2021 and the published unaudited figures for the half year ended on September 30, 2021
- 3 The above Financial Results for the quarter and nine month ended on 31st December 2021 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Friday, 11th February 2021.
- 4 The results for the quarter and nine month ended on 31st December 2021 are subject to "limited Review" by the Auditors and their report contains no qualification.
- 5 Depreciation on fixed assets is provided on Written down Value method as per the estimated remaining useful life of assets.
- 6 The Company has identified "Pharmaceuticals Manufacturing" as the single operating segment for the continued operations in the financial statements as per Ind AS 108 "Operating Segments".
- 7 The Company continues to consider the impact of COVID-19 pandemic in assessing the recoverability of receivables, inventories and other assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. The Company based on its judgements, estimates and assumptions including sensitivity analysis expects to fully recover the carrying amount of receivables, inventories and other assets. The Company will continue to closely monitor any material changes to future economic conditions.
- 8 Figures for the previous periods have been regrouped, wherever necessary.
- 9 Revenue from Operations is shown exclusive of GST
- 10 Earnings per share amount shown in Rupees.

Place : Indore
Date : 11.02.2022

By Order of the Board
For Beryl Drugs Limited
Shri
Shri Jay Sethi
Managing Director
DIN : 00090277

PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS

212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,

INDORE (M.P.) 452001

PH. 9827013187, 731-2520955

E-MAIL: caprateekjain@gmail.com



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read with SEBI Circular No. CIRJCFD/CMDI/44/2019 dated March 29, 2019

To,
The Board of Directors
Beryl Drugs Limited
133, Kanchan Bagh,
Indore (M.P.) - 452001

We have reviewed the accompanying statement of unaudited financial results ("the Statement") of **BERYL DRUGS LIMITED** ("the Company") for the quarter ended **December 31, 2021 and year to date from April 01, 2021 to December 31, 2021**. The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

This statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind As 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



PRATEEK JAIN & CO.


CHARTERED ACCOUNTANTS

212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,

INDORE (M.P.) 452001

PH. 9827013187, 731-2520955

E-MAIL: caprateekjain@gmail.com



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR PRATEEK JAIN AND CO.
CHARTERED ACCOUNTANTS

ERN-009494C



Prateek Jain

PRATEEK JAIN
PROPRIETOR

M. No.079214

Date: 11th February, 2022

Place: Indore

UDIN: 22079214ABIQK1674